Rachel Rowling, MBA

My role is to overseas our B2B, B2C, and B2B2C global operations across 4 brands with product, marketing and system development. We support our healthcare partners (and the technology underpinning) with patient acquisition and patient navigation across multiple treatment categories in over 30+ countries.

Our overall B2B goal is to maximize partner capacity, reduce complexity, and streamline shared costs and resources. Our B2C goal is to provide high-quality, affordable, and safe options for medical travelers and remote individuals. By having a combined B2C and B2B focus, we can better drive healthcare solutions that benefit partners and connected patients and solve real business and personal challenges.

Our B2B2C focus is working with leading global hospitals and universities, in AI technologies to simplify complex cancer assessment, treatment plans, onsite and virtual second opinions that connect cancer patients to advanced cancer therapies around the world.

From an investor view, I support the President, identify and source new investors, and communicate scheduled strategic and operational updates to existing investors.

Yasuhiro Hashimoto, MD

Dr. Yasuhiro Hashimoto is a graduate of Osaka University Medical School and did his postdoctoral research at the Harvard University Medical School. He has been an Associate Professor at the University of Pennsylvania, Senior Director of the Institute of Immunology at Syntex in Japan, Director of Biotechnology at the Department of Roche Bioscience (US) and Director of Molecular Biology Department for the Tsukuba Laboratory of Nippon Glaxo Ltd (currently GlaxoSmithKline K.K.).

In 2000, he founded MediBIC and was the President and CEO of the company until 2013. Medibic Group, was listed on the Tokyo Stock Exchange in 2003. The Group was awarded the “Minister’s Award for Best Entrepreneurs and Venture Capitalists” by the Ministry of Industry and the “Most rapidly growing technology company in Japan”, by Deloitte Touche Tohmatsu. Dr. Hashimoto has also been on the board of directors of several Asian biotech companies.

Dr.Hashimoto is currently involved and helping with four start-up Biotech and Healthcare companies. He is currently a President at Taqtik Health, Sunnyvale California.